Literature DB >> 20843255

From palliation to targeted therapy in myelofibrosis.

Alessandro M Vannucchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20843255     DOI： 10.1056/NEJMe1005856

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  Preclinical models for drug selection in myeloproliferative neoplasms.

Authors:  Niccolò Bartalucci; Costanza Bogani; Alessandro M Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

2.  Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

Authors:  Paola Guglielmelli; Giovanni Barosi; Alessandro Rambaldi; Roberto Marchioli; Arianna Masciulli; Lorenzo Tozzi; Flavia Biamonte; Niccolò Bartalucci; Elisabetta Gattoni; Maria Letizia Lupo; Guido Finazzi; Alessandro Pancrazzi; Elisabetta Antonioli; Maria Chiara Susini; Lisa Pieri; Elisa Malevolti; Emilio Usala; Ubaldo Occhini; Alberto Grossi; Silvia Caglio; Simona Paratore; Alberto Bosi; Tiziano Barbui; Alessandro M Vannucchi
Journal:  Blood       Date:  2011-07-01       Impact factor: 22.113

3.  JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.

Authors:  Alessandro M Vannucchi; Lisa Pieri; Paola Guglielmelli
Journal:  Ther Adv Hematol       Date:  2011-02

4.  Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.

Authors:  Claire Harrison; Alessandro M Vannucchi
Journal:  Ther Adv Hematol       Date:  2012-12

5.  Serum Interleukin-15 is a Marker of Alopecia Areata Severity.

Authors:  Adel Ali Ebrahim; Rehab Mohammed Salem; Asmaa Adel El Fallah; Esraa Taha Younis
Journal:  Int J Trichology       Date:  2019 Jan-Feb
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.